Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928261 | 0.84 | P2RX7 (0.33) | P2RX7BRD4 | |
| SCHEMBL9990128 | 0.83 | — | — | |
| SCHEMBL28521208 | 0.79 | P2RX7 (0.39) | P2RX7BRD4 | |
| SCHEMBL927982 | 0.73 | P2RX7 (0.31) | P2RX7BRD4 | |
| SCHEMBL1313231 | 0.73 | SMYD3 (0.44) | P2RX7 | |
| Hydrochloric Acid SCHEMBL19995691 | 0.72 | SMYD3 (0.43) | P2RX7 | |
| SCHEMBL21814069 | 0.68 | GABRA1 (0.31) | — | |
| SCHEMBL22233169 | 0.68 | CYP2D6 (0.30) | P2RX7 | |
| SCHEMBL4793570 | 0.67 | SMYD3 (0.37) | P2RX7 | |
| SCHEMBL17606550 | 0.67 | SMYD3 (0.37) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | MC1R, MCHR1, MCHR2 | P2RX7 938/4885BRD4 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.